广西南宁市蓝添化工有限公司

Headquarter: Chemical Industry Park, Economic Development Zone,  JiNan City,  ShanDong Province, China.

Phone +86-152 8958 7728

Angela@BlueSkytcca.com
Pulmonary Delivery of Orally Inhaled Therapeutics

Approval given to Turkish based Omya for API production – OutSourcing-Pharma.com

Or wait…
Headlines
Preclinical Research
Drug Delivery
Ingredients
Clinical Development
Contract Manufacturing & Logistics
Markets & Regulations
Promotional Features
Site Archive
Multimedia
Hot Topics
Globalization
Mergers and Acquisitions
Bioavailability Challenge
COVID-19
Patient centricity
Clinical evolution
Transparency on trial
Site Archive
Multimedia
Resources
Type of resources
Events
All Events
Editorial Webinars
Events
Related Site

– Last updated on GMT
Related tags API Active pharmaceutical ingredients Manufacturing Gmp Supply chain Pharmacology
Now the company has the official Turkish Health Authority accreditation it can manufacture calcium carbonate as an API.
The site called Omya is working in line with the strictest quality requirements and industry-leading GMP-compliant manufacturing practices set out in the good manufacturing practice guide.
Together with its manufacturing sites in the USA and France, this is for Omya now the third fully certified plant supplying the pharma, nutraceutical, and food industries.
The plant is also compliant with the international ISO standards of basic quality, environment and work safety.
The company’s mineral particles are processed in Turkey from high-purity marble stone in accordance with the most stringent sustainability and quality standards, and with a very low environmental footprint. In the plant, ultrapure and white calcium carbonate is processed to various morphologies, thus offering a broad range of products with multiple functionalities.
The company says the resulting mineral ingredients designated for the pharmaceutical industry under the brand name Omyapure offer numerous benefits for finished products, facilitate production processes and increase nutritional profiles. As such, Omyapure can be used in antacid products as well as osteoporosis treatments.
To successfully operate the plant while preserving and protecting its delicate surroundings, Omya says it is highly considerate of the environment in all areas of its activity.
Stefan Lander, vice president consumer goods, at Omya, said: “Having our third plant now certified for the production of pharmaceutical actives and expanding our offerings from Kemalpasa in Turkey will help us serve our global customers with natural and highly functional minerals, while maintaining a focus on economic and ecological efficiency, which is fully aligned with Omya’s purpose of making life better through our passion for minerals and chemistry.”

Copyright - Unless otherwise stated all contents of this web site are © 2023 - William Reed Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Related topics Clinical Development Contract Manufacturing & Logistics Markets & Regulations Ingredients APIs (active pharmaceutical ingredients) Delivery formulations Delivery technologies Excipients, raw materials and intermediates
Show more
Pulmonary Delivery of Orally Inhaled Therapeutics
Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice
New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...
Manufacturing Drugs with Highly Potent APIs
Content provided by Altasciences | 28-Sep-2023 | White Paper
In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...
In Vivo Evaluation of a Gastro-Resistant HPMC-Based “Next Generation Enteric” Capsule
Content provided by Lonza Capsules & Health Ingredients | 01-Sep-2023 | White Paper
Invivo: Many orally dosed APIs are bioavailable only when formulated as an enteric dosage form to protect them from the harsh environment of the stomach....
An optimized Plasmid DNA platform to accelerate the path to clinic and commercialization
Recipharm AB | Recorded the 14-Sep-2023 | Webinar
Assessing key parameters of the upstream process to achieve high titer while maintaining desired integrity
Customizing the downstream process to...
Register for free
Show more
Upcoming editorial webinars
On-demand webinars
More promotional features

source

Leave a Reply

Your email address will not be published.

*